Investment Institute
Multi Asset

Multi-Asset Investments Views: Homeward bound

KEY POINTS

Marginally reduced our overweight to equities
The widely-anticipated year-end rally was a late but welcome appearance. The November to December period proved to be clumsy, with equity markets struggling to regain the momentum which had recently been so heavily penalised. A pick-up in volatility pricing, albeit from muted levels, weighed on sentiment. Markets focused primarily on communication surrounding the Federal Reserve’s December meeting which, despite delivering the expected Fed Funds Rate cut, nevertheless exposed a growing lack of consensus for the path of future policy. We opted to reflect this increased uncertainty by marginally reducing the overweight stance of our equity allocation
Further concentrating equity exposure towards Europe
A great deal of ink has been spent on the short to medium-term impact of the AI capex boom on earnings, GDP and productivity growth. While we do not believe from a valuation perspective equity indices are in a bubble, the last quarter witnessed a noticeable cooling of investor appetite towards the AI theme and high momentum trades in the US. We reduced our exposure to technology stocks by cutting some exposure in the Nasdaq and China tech indices. We maintained our allocation to the Eurozone and its financial sector, which increases its relative importance in our tactical overlay. We also retained our emerging markets exposure via broad China equity indices
Exited short-dated German bonds
While we remain convinced the ECB’s increasingly hawkish stance is somewhat over-zealous (given the persistent weakness in European exports, currency strength, softer energy prices and the ongoing risk of imported deflation from China), we acknowledge the move in market pricing and the persistence of positive macro surprises. We therefore closed our position on short-dated German government bonds and adopted a neutral exposure in terms of interest rate sensitivity

The US Federal Reserve (Fed) delivered its third interest rate cut in a row in December - despite the absence of much public macroeconomic data due to the US government shutdown, and questions hanging over the quality of some of the data which was subsequently published.

There was some volatility surrounding monetary policy going into 2026 (with two policymakers voting for no policy change). The Fed board consensus under Chair Jerome Powell has begun to break down. This has had a mildly negative impact on investor confidence, but President Donald Trump’s appointment of the next Fed Chair will materially shift the focus to further policy accommodation. Beyond that, the recent credible macro numbers have been supportive for further easing without raising concerns for a more marked deterioration either in the labour market or inflation. The Fed is faced with a bifurcated economy whereby lower income households and small businesses require some policy help, yet the rest of the economy is doing very well, as aggregate GDP growth and corporate earnings continue to show.

For the Eurozone, markets have begun to price the possibility of a European Central Bank (ECB) rate hike in 2026, largely due to fears the German fiscal boost, along with lagged spending for the NextGenerationEU programme (especially in Italy), will raise the neutral rate for the Eurozone as a whole.


We have marginally reduced our strong allocation to equity markets. Our quantitative signals play a foundational role in the construction of our investment views and their translation into our portfolio construction. In general, we have seen a weakening of the intensity of the positive signals that had accompanied our decision to increase risk in our equity allocation. While the intensity has clearly abated, it is only to a neutral level rather than a negative one.

The small rise in uncertainty in the US monetary policy outlook following the Fed’s December meeting was a negative factor, along with small moves in market volatility pricing. Adding some optionality into the start of the year, by receding marginally from near-maximum levels of risk appetite for our portfolios, indicates some prudence rather than any fundamental concerns. We remain significantly overweight equities.

We have maintained a keen focus on the evolution of investor sentiment and positioning indicators to appreciate the potential for new investor flows into or out of asset classes, but especially in equity markets. A common theme we have revisited this year has been the weak support from discretionary investors since the extreme moves seen in April and May. While falling levels of volatility have driven systematic investors – those who use data-led quantitative models to make decisions - to re-engage with risk, their discretionary counterparts appear to have been reluctant to engage above neutral on an aggregate basis.

More recently, retail investors proved less aggressive in countering market weakness to increase their positions. We are encouraged that the recent brief spikes in volatility have reduced systematic positions from elevated levels, while discretionary investors will likely be forced to chase the market from historically prudent levels of equity risk exposure. This means that, bar a new shock, we see space for investors to add to their equity positioning.

We remain neutral (structurally invested) on credit, as we prefer to concentrate our positive risk assessment within equity markets. Flows into the investment-grade market have again been strong in 2025, despite some concerns surrounding the increasing demand for financing from technology companies to build AI infrastructure with borrowing rather than from cash reserves. High yield has generally lagged these flows from investors, as spreads have hovered around historically tight levels. While investment-grade investors have shunned government bond markets in favour of tapping marginally higher yields in credit for their duration needs, it appears high yield investors have likely looked for better risk-reward from equity markets in their allocations.  

The combination of further policy accommodation from the Fed (and other central banks), lagged impacts from ECB easing, fiscal stimulus in the US, Eurozone, Japan and perhaps China, plus resilient corporate earnings and the rising probability of ceasefire in Ukraine, all underpin a favourable setting for the start of 2026. We wish you all the best for this new year, from health to happiness and great financial returns.

Source: Citigroup, as at 31 December 2025

Have our latest insights delivered straight to your inbox

SUBSCRIBE NOW

    Disclaimer

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of BNP PARIBAS ASSET MANAGEMENT Europe or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ.

    Back to top